Compare KPTI & LFVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KPTI | LFVN |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 145.2M |
| IPO Year | 2013 | N/A |
| Metric | KPTI | LFVN |
|---|---|---|
| Price | $6.95 | $6.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $22.17 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 174.4K | 148.9K |
| Earning Date | 11-03-2025 | 11-04-2025 |
| Dividend Yield | N/A | ★ 2.77% |
| EPS Growth | N/A | ★ 143.91 |
| EPS | N/A | ★ 0.78 |
| Revenue | $142,530,000.00 | ★ $228,877,000.00 |
| Revenue This Year | $3.82 | $1.54 |
| Revenue Next Year | $3.18 | $7.00 |
| P/E Ratio | ★ N/A | $8.34 |
| Revenue Growth | N/A | ★ 16.77 |
| 52 Week Low | $3.51 | $5.98 |
| 52 Week High | $12.45 | $27.38 |
| Indicator | KPTI | LFVN |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 39.73 |
| Support Level | $5.70 | $6.34 |
| Resistance Level | $6.05 | $6.78 |
| Average True Range (ATR) | 0.45 | 0.30 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 75.69 | 19.75 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Lifevantage Corp is engaged in the identification, research, development, and distribution of nutraceutical dietary supplements and skincare products. It offers products such as Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skincare product; Axio energy drink mixes; and PhysIQ, a weight management system and other product Geographically, its products are sold in the regions of the United States, Japan, Hong Kong, Australia, Canada, Philippines, Mexico, Thailand, the United Kingdom, and the Netherlands.